Karl Stéfic1,2, Mélanie Bouvin-Pley1, Asma Essat3,4, Clara Visdeloup1, Alain Moreau1, Cécile Goujard3,4, Marie‐Laure Chaix5,6, Martine Braibant1, Laurence Meyer3,4, Françis Barin1,2
1INSERM U1259, Université de Tours, Tours, France
2Laboratoire de Virologie and CNR VIH-Laboratoire Associé, Centre Hospitalier Régional Universitaire de Tours, Tours, France
3Assistance Publique-Hôpital de Paris, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
4Inserm U1018, Université Paris Saclay, CESP, Paris, France
5Assistance Publique-Hôpital de Paris, Laboratoire de Virologie and CNR VIH, Hôpital Saint-Louis, Paris, France
6INSERM U941, Université Paris Diderot, Paris, France
Tóm tắt
Major progress occurred during the last decade leading to the isolation of human monoclonal antibodies, termed broadly neutralizing antibodies (bnAbs) due to their capacity to neutralize various strains of HIV-1. Several clinical trials are under way in order to evaluate their efficacy in preventive or therapeutic strategies. However, no single bnAb is active against 100% of strains. It is important to gather data on the sensitivity to neutralizing antibodies of all genotypes, especially those more widespread in regions where the prevalence of HIV-1 infection is high. Here, we assembled a large panel of clade CRF02_AG viruses, the most frequent genotype circulating in West Africa and the second most frequent found in several European countries. We evaluated their sensitivities to bnAbs, including those most advanced in clinical trials, and looked for the best combinations. In addition, we observed a trend toward increased resistance to bnAbs over the course of the epidemic.
